← All organizations
Highest phase reached
Phase 3
First clinical trial
Mar 1, 1998Last known activity
Sep 30, 2025
Timeline
1980s
- Jan 1, 1988
National Institute on Deafness and Other Communication Disorders (NIDCD)— Founded
Drugs by trial phase (44 distinct, 31 trials)
Phase 3 (13 own, 0 via acquisition)
Phase 2 (10 own, 0 via acquisition)
Phase 1 (9 own, 0 via acquisition)
Other trials (12 own, 0 via acquisition)
Indications
Studied for
- Autistic Disorder
- Carcinoma
- Carcinoma, Squamous Cell
- Deafness
- Dysphonia
- Ear Diseases
- Essential Tremor
- Head and Neck Neoplasms
- Hearing Loss
- Hearing Loss, Noise-Induced
- Hearing Loss, Sensorineural
- Hearing Loss, Sudden
- Hoarseness
- Labyrinth Diseases
- Labyrinthitis
- Laryngeal Neoplasms
- Mouth Neoplasms
- Otitis
- Otitis Media
- Papilloma
- Papillomavirus Infections
- Paralysis
- Parkinson Disease
- Pharyngeal Neoplasms
- Respiratory Tract Infections
- Squamous Cell Carcinoma of Head and Neck
- Tinnitus
- Tremor
Recent trials (34)
- NCT07215884CollaboratorPhase 1Sep 30, 2025
- NCT06461949OfficialPhase 3Jul 17, 2024
- NCT06461949Lead sponsorPhase 3Jul 17, 2024
- NCT05730283CollaboratorPhase 2Aug 1, 2023
- NCT04915183Overall official - principal investigatorPhase 3Dec 7, 2021
- NCT04915183Lead sponsorPhase 3Dec 7, 2021
- NCT04028674CollaboratorEarly Phase 1Sep 30, 2019
- NCT03107871CollaboratorPhase 3Oct 1, 2017
- NCT03292458CollaboratorPhase 2/Phase 3Sep 1, 2017
- NCT02567825CollaboratorN/ANov 30, 2015
- NCT02390089CollaboratorPhase 1Apr 1, 2015
- NCT01925729CollaboratorN/AOct 1, 2013
- NCT01925482CollaboratorN/ASep 1, 2013
- NCT01950312CollaboratorPhase 2Aug 1, 2013
- NCT01864525CollaboratorPhase 1/Phase 2Jul 1, 2013
Details
- Founded
- Bethesda, MD, US Jan 1, 1988
- Last known activity
- Sep 30, 2025